Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04898751 · ClinicalTrials.gov registry record
Analysis of Reporting of Cutaneous Toxicities Associated With Immune Checkpoint Inhibitors
A clinical trial of Cutaneous Toxicity From ICI Therapy, sponsored by Johns Hopkins University.
- Completed
- Registry status
- 2,214
- Enrollment target
- 1
- Study location
NCT04898751 is a study of Cutaneous Toxicity From ICI Therapy that has completed, run by Johns Hopkins University. The registered enrollment target is 2,214 participants. The trial reports 1 study location across 1 state.
The verdict
NCT04898751, a study of Cutaneous Toxicity From ICI Therapy, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- 2,214 participants
- Enrollment target
- 1
- Study location
Study Summary
Immune checkpoint inhibitors (ICIs) are associated with a wide variety of cutaneous immune-related adverse events (cirAEs). These cirAEs are reported to be the most common immune-related adverse events (irAEs) and the first to appear. This study examines the appearance of cirAEs within the World Health Organization (WHO) pharmacovigilance database, VigiBase.
Conditions Studied
Interventions
- DRUG Immune checkpoint inhibitor (ICI)
Study Locations (1)
Maryland
- Sidney Kimmel Comprehensive Care Center - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,214 participants |
| Start Date | 2008-01-01 |
| Est. Completion | 2020-08-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04898751
The ClinicalTrials.gov registry entry for NCT04898751 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 2,214 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cutaneous Toxicity From ICI Therapy appearing as the primary indexed condition, and to 1 intervention - of which Immune checkpoint inhibitor (ICI) is the first listed.
NCT04898751 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT04898751 about?
NCT04898751 is a clinical study titled "Analysis of Reporting of Cutaneous Toxicities Associated With Immune Checkpoint Inhibitors". Immune checkpoint inhibitors (ICIs) are associated with a wide variety of cutaneous immune-related adverse events (cirAEs). These cirAEs are reported to be the most common immune-related adverse events (irAEs) and the first to appear. This study examines the appearance of cirAEs within the World Hea...
What is the current status of trial NCT04898751?
This trial is currently completed. The enrollment target is 2,214 participants. The study started on 2008-01-01. Estimated completion is 2020-08-31.
What conditions does trial NCT04898751 study?
This clinical trial studies the following conditions: Cutaneous Toxicity From ICI Therapy.
What interventions are being tested in trial NCT04898751?
The interventions under investigation include: Immune checkpoint inhibitor (ICI) (DRUG).
Who is sponsoring clinical trial NCT04898751?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04898751 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.